Clinical trial
Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the…
NCT00316264 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00316264 |
|---|---|
| Title | Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season |
| Official title | A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Respiratory Syncytial Virus Infections, Chronic Lung Disease and <= 24 Months of Age or, Premature With Gestational Age <=35 Weeks and <=6 Months of Age |
| Intervention type | Biological |
| Interventions | Motavizumab, palivizumab, Palivizumab, motavizumab |
| Enrollment | 260 |
| Start date | Apr 1, 2006 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Apr 20, 2006 |
| Last update posted | Dec 11, 2012 |
| Countries | Australia, Chile, New Zealand |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: